Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2007 | Technical innovations

Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma

Authors: Maciej W Slupski, Cezary Szczylik, Milosz K Jasinski

Published in: World Journal of Surgical Oncology | Issue 1/2007

Abstract

Background

Cholangiocellular cancers account for about 10-15% of primary liver cancers. Prognosis is poor, with expected survival of less than 5% at five-year.

Case presentation

The case described shows remission of a disseminated cholangiocellular carcinoma (focal changes in liver, metastases to lungs) after neoadjuvant chemotherapy. The initial diagnosis was based on ultrasound examination and confirmed with computer tomography. Tumour biopsy and histopathological examination revealed cholangiocellular carcinoma. The patient underwent chemotherapy. After remission of lesions in lungs and reduction/regression of tumours in liver to one focal change, right lobe liver resection was performed. The histopathological examination did not reveal any viable carcinoma cells, only necrotic tissues in place of the primary tumour as well as in local portal vein branches was seen. Thirty months after the operation the patient is in a good overall condition and no recurrence has been observed.

Conclusion

Appropriate neoadjuvant chemotherapy may allow radical resection in a previously unresectable cholangiocellular cancer.

Available only for authorised users

Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 1999, 19: 271-285.CrossRefPubMed

Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V: Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev. 1993, 2 (6): 537-544.PubMed

Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B: Surgical treatment of cholangiocellular carcinoma. World J Surg. 1995, 19: 83-88. 10.1007/BF00316984.CrossRefPubMed

Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J: Resection of intrahepatic cholangiocarcinoma; a Western experience. J Hepatobiliary Pancreat Surg. 1999, 6: 122-127. 10.1007/s005340050094.CrossRefPubMed

Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM: Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg. 1998, 5: 41-47. 10.1007/PL00009949.CrossRefPubMed

Weimann A, Varnholt H, Schlitt HJ, Lang H, Flemming P, Hustedt C, Tusch G, Raab R: Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg. 2000, 87: 1182-1187. 10.1046/j.1365-2168.2000.01532.x.CrossRefPubMed

Fu XH, Tang ZH, Zong M, Yang GS, Yao XP, Wu MC: Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int. 2004, 3: 279-283.PubMed

Franca AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ: Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004, 37: 1689-1705. 10.1590/S0100-879X2004001100015.CrossRefPubMed

Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004, 15 (5): 770-774. 10.1093/annonc/mdh172.CrossRefPubMed

10.

Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002, 51: 1-9. 10.1136/gut.51.1.1.CrossRef

11.

Scheithauer W: Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002, 29 (6 Suppl 20): 40-45.CrossRefPubMed

12.

Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C: Phase II trial of intravenous flourouracil and subcutaneous interferon K-2b for biliary tract cancer. J Clin Oncol. 1996, 14: 2311-2315.PubMed

13.

Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998, 9 (6): 653-656. 10.1023/A:1008241008379.CrossRefPubMed

14.

Harvey JH, Smith FP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984, 2: 1245-1248.PubMed

15.

Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002, 13: 1192-1196. 10.1093/annonc/mdf201.CrossRefPubMed

16.

Mitry E, Van Cutsem E, Van Laethem JL: A randomized phase II trial of weekly high dose 5-FU (HD-FU) with and without folinic acid (FA) and cisplatin (P) in patients with advanced biliary tract carcinoma: the EORTC 40955 trial. Proc Am Soc Clin Oncol. 2002, 21: 175-(Abstr 698)

17.

Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-FU/leucovorin/mitomycin and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999, 56: 177-180. 10.1159/000011961.CrossRefPubMed

18.

Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I: Phase II trial of cisplatin, interferon K-2b, doxorubicin, and fluorouracil for biliary tract cancer. Clin Cancer Res. 2001, 7: 3375-3380.PubMed

Title: Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma
Authors: Maciej W Slupski
Cezary Szczylik
Milosz K Jasinski
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2007
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-5-36

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma

Abstract

Background

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Acute adrenal crisis after orthopedic surgery for pathologic fracture

Prostatic sarcoma after treatment of rectal cancer

Cavernous lymphangioma of the breast

A multimodality localization technique for radio-guided surgery

Extramedullary plasmacytoma (EMP): Report of a case manifested as a mediastinal mass and multiple pulmonary nodules and review of literature

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma